Cellular components in hyperproliferating epidermal cells

Cellular components in hyperproliferating epidermal cells is a descriptive term used in pharmacology to categorize the site of action for non-specific antipsoriatic drugs like anthralin and coal tar (DrugBank DB00485). These substances are primarily utilized to manage psoriasis, a chronic autoimmune condition characterized by the rapid and excessive growth of skin cells (StatPearls, NBK482225). The term reflects a historical lack of a single, identified molecular receptor or enzyme that mediates the therapeutic effects of these treatments. Instead, these drugs are believed to act through multiple pathways, including the disruption of mitochondrial function and the inhibition of DNA synthesis within keratinocytes (PubChem CID 2202). By interfering with the energy supply and genetic replication of these hyperactive cells, the drugs effectively reduce the rate of epidermal turnover. Despite their long-standing clinical use, the specific molecular entities involved remain a subject of ongoing research, often involving the generation of free radicals and the modulation of inflammatory signaling. This lack of specificity is a hallmark of older topical therapies that target the cellular state of hyperproliferation rather than a distinct protein.

Other names

Unknown cellular components in hyperproliferating epidermal cellsPsoriatic keratinocyte componentsHyperproliferative epidermal cell targets

Inhibition of DNA synthesis and mitochondrial function leading to reduced keratinocyte proliferation.